Highlights: Cangrelor significantly reduces ischaemic events compared with clopidogrel; transcatheter aortic valve still works after three years in high-risk patients; novel drug could reduce heart damage during angioplasty. Profile: Morton Kern
[pdfviewer width=”100%” height=”940px” beta=”true”]http://cardiovascularnews.com/wp-content/uploads/sites/14/2016/06/CVN-Issue-29-EU.pdf[/pdfviewer]
